Champlain Investment Partners LLC grew its position in Medidata Solutions Inc (NASDAQ:MDSO) by 1.5% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,390,155 shares of the company’s stock after purchasing an additional 35,405 shares during the quarter. Medidata Solutions makes up 1.5% of Champlain Investment Partners LLC’s portfolio, making the stock its 13th biggest position. Champlain Investment Partners LLC’s holdings in Medidata Solutions were worth $175,055,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc boosted its position in Medidata Solutions by 2.8% during the 3rd quarter. Vanguard Group Inc now owns 5,200,744 shares of the company’s stock worth $381,266,000 after buying an additional 142,687 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in Medidata Solutions during the 4th quarter worth approximately $90,000. Rhumbline Advisers boosted its position in Medidata Solutions by 62.8% during the 4th quarter. Rhumbline Advisers now owns 183,326 shares of the company’s stock worth $12,360,000 after buying an additional 70,690 shares during the period. Benjamin F. Edwards & Company Inc. boosted its position in Medidata Solutions by 127.2% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 945 shares of the company’s stock worth $64,000 after buying an additional 529 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its position in Medidata Solutions by 3.1% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 36,485 shares of the company’s stock worth $2,460,000 after buying an additional 1,103 shares during the period.

MDSO has been the topic of several recent research reports. TheStreet upgraded shares of Medidata Solutions from a “c+” rating to a “b-” rating in a research report on Friday, March 15th. Zacks Investment Research upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating and set a $83.00 target price on the stock in a research report on Tuesday, February 12th. Guggenheim initiated coverage on shares of Medidata Solutions in a research report on Wednesday, April 17th. They set a “buy” rating and a $92.00 target price on the stock. SunTrust Banks downgraded shares of Medidata Solutions from a “buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research report on Wednesday, April 24th. Finally, Wells Fargo & Co downgraded shares of Medidata Solutions from an “outperform” rating to a “market perform” rating and set a $90.00 target price on the stock. in a research report on Tuesday, April 23rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $84.23.

Medidata Solutions stock opened at $94.75 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.57 and a quick ratio of 2.57. Medidata Solutions Inc has a 52-week low of $60.10 and a 52-week high of $98.60. The company has a market cap of $5.90 billion, a price-to-earnings ratio of 98.70, a PEG ratio of 8.43 and a beta of 1.31.

Medidata Solutions (NASDAQ:MDSO) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.33. Medidata Solutions had a net margin of 7.99% and a return on equity of 9.28%. The firm had revenue of $173.50 million during the quarter, compared to analyst estimates of $172.12 million. During the same quarter last year, the business earned $0.40 EPS. The company’s revenue was up 16.3% compared to the same quarter last year. Analysts forecast that Medidata Solutions Inc will post 0.79 earnings per share for the current year.

In other Medidata Solutions news, Director Robert Taylor sold 3,294 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $90.88, for a total transaction of $299,358.72. Following the completion of the transaction, the director now owns 41,757 shares in the company, valued at approximately $3,794,876.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.70% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Medidata Solutions Inc (NASDAQ:MDSO) Position Boosted by Champlain Investment Partners LLC” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/medidata-solutions-inc-nasdaqmdso-position-boosted-by-champlain-investment-partners-llc/3039186.html.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.

Featured Story: What is the price-sales ratio?

Want to see what other hedge funds are holding MDSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medidata Solutions Inc (NASDAQ:MDSO).

Institutional Ownership by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.